S-1/A: Tenax Therapeutics Eyes $12 Million in Public Offering to Fuel Levosimendan Trial

Tenax Therapeutics aims to raise up to $12 million through a public offering of common stock, warrants, and pre-funded warrants to advance its oral levosimendan (TNX-103) Phase 3 trial for pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF).

Summary

• Tenax Therapeutics is launching a best efforts public offering to raise up to $12 million.
• The offering includes shares of common stock and warrants to purchase additional shares.
• Pre-funded warrants are also available for purchasers exceeding beneficial ownership limits.
• Proceeds will primarily fund the LEVEL trial, a Phase 3 study of oral levosimendan (TNX-103) for PH-HFpEF.
• The offering is expected to close by February 14, 2024, with Roth Capital Partners, LLC acting as the exclusive placement agent.
• The company has prioritized the LEVEL trial and suspended plans for an imatinib Phase 3 trial.
• The company has two U.S. patents covering the use of IV and oral levosimendan in patients with PH-HFpEF.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the potential of Tenax's lead drug candidate and the company's plans to advance its clinical development, it also acknowledges the company's financial challenges, including its going concern status and the need for additional funding. The document also mentions the competitive landscape and the risks associated with drug development and commercialization.

Positives

• Proceeds will primarily fund the LEVEL trial, a Phase 3 study of oral levosimendan (TNX-103) for PH-HFpEF.
• The company has two U.S. patents covering the use of IV and oral levosimendan in patients with PH-HFpEF.
• FDA has reviewed and cleared the Companys Investigational New Drug (IND) Application for TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), enabling Tenax to proceed with the first of two Phase 3 studies.

Negatives

• This is a best efforts offering, no minimum amount of securities is required to be sold, and we do not expect to raise the amount of capital we believe is required for our business plans.
• There is no public market for the Warrants or Pre-Funded Warrants.
• The Warrants in this offering are speculative in nature.
• Holders of the Warrants and Pre-Funded Warrants will not have rights of holders of our shares of Common Stock until such Warrants or Pre-Funded Warrants are exercised.
• If you purchase shares of Common Stock in this offering, you will incur immediate and substantial dilution in the book value of the shares of our Common Stock.

Risks

• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company needs additional funding to complete the LEVEL trial and may need to delay, limit, or terminate clinical trials if funding is not secured.
• The company's exploration of strategic alternatives may not result in a transaction.
• Failure to regain compliance with Nasdaq's continued listing requirements could result in the delisting of the company's common stock.
• The company has incurred losses since its inception and expects to continue to incur losses in the foreseeable future.

Future Outlook

The company intends to use the net proceeds from this offering to initiate additional research sites and advance the enrollment and treatment of patients in the LEVEL trial, as well as working capital, capital expenditures, and other general corporate purposes.

Industry Context

The document highlights Tenax Therapeutics' focus on developing therapies for cardiopulmonary diseases, particularly PH-HFpEF, where there are currently no approved pharmacologic treatments. The company is competing in a competitive pharmaceutical and biotechnology landscape with many companies developing drugs for cardiovascular, pulmonary, and related medical conditions.

Comparison to Industry Standards

• The document mentions Novartis's previous development of imatinib for PAH, including a Phase 3 trial that met its primary endpoint but was ultimately withdrawn due to tolerability issues.
• The document notes that several other companies are developing new therapies to treat PAH, including some that may also be disease-modifying.
• The document states that pulmonary vasodilators are the only approved medications for PAH, but they do not have disease-modifying properties.

Stakeholder Impact

• Shareholders may experience dilution from the issuance of new shares.
• Employees' job security is dependent on the company's ability to secure additional funding.
• Patients with PH-HFpEF may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial condition.

Next Steps

• Initiate additional research sites and advance the enrollment and treatment of patients in the LEVEL trial.
• Continue to explore strategic alternatives, including a sale of the company, merger, or other business combination.
• Seek additional funding through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements.

Key Dates

Keywords

Tenax Therapeutics, public offering, levosimendan, TNX-103, PH-HFpEF, warrants, pre-funded warrants, LEVEL trial, Roth Capital Partners, imatinib